Skip to main content
main-content

12-09-2019 | Multiple sclerosis | Video

ECTRIMS 2019: Timely and continuous therapy reduces conversion to progressive MS

Pietro Iaffaldano comments on real-world data showing risk factors associated with increased conversion from relapsing-remitting multiple sclerosis to secondary progressive disease (4:31).

Funding for this video was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits